3-Chlor-9,10-phenanthrenchinon | 56961-99-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: 3-Chlor-9,10-phenanthrenchinon
• 英文别名: 3-chlorophenanthrene-9,10-dione
• CAS: 56961-99-0
• 化学式: C₁₄H₇ClO₂
• 分子量: 242.661
• InChiKey: LCTGTYWQCIPXLD-UHFFFAOYSA-N

物化性质

• 熔点：
  261 °C(Solv: acetic acid (64-19-7))
• 沸点：
  431.0±24.0 °C(Predicted)
• 密度：
  1.418±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-Chlor-9,10-phenanthrenchinon 在 乙醇 、 盐酸羟胺 作用下， 生成 3-chloro-phenanthrene-9,10-dione monooxime
  参考文献：
  名称：

  Sandqvist; Hagelin, Chemische Berichte, 1918, vol. 51, p. 1520

  摘要：

  DOI：
• 作为产物：
  描述：

  3-乙酰基菲 在 吡啶 、 chromium(VI) oxide 、 亚硝酸特丁酯 、 PPA 、 盐酸羟胺 、 copper dichloride 作用下， 以 乙醇 、 溶剂黄146 、 乙腈 为溶剂， 反应 8.75h， 生成 3-Chlor-9,10-phenanthrenchinon
  参考文献：
  名称：

  WO2007/124589

  摘要：

  公开号：

文献信息

• Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors
  作者：Bernard Côté、Louise Boulet、Christine Brideau、David Claveau、Diane Ethier、Richard Frenette、Marc Gagnon、André Giroux、Jocelyne Guay、Sébastien Guiral、Joseph Mancini、Evelyn Martins、Frédéric Massé、Nathalie Méthot、Denis Riendeau、Joel Rubin、Daigen Xu、Hongping Yu、Yves Ducharme、Richard W. Friesen

  DOI：10.1016/j.bmcl.2007.10.033

  日期：2007.12

  Phenanthrene imidazole 3 (MF63) has been identified as a novel potent, selective, and orally active mPGES-1 inhibitor. This new series was developed by lead optimization of a hit from an internal HTS campaign. Compound 3 is significantly more potent than the previously reported indole carboxylic acid 1 with an A549 whole cell IC(50) of 0.42 microM (50% FBS) and a human whole blood IC(50) of 1.3 microM

  菲咪唑3（MF63）已被鉴定为新型有效，选择性和口服活性的mPGES-1抑制剂。这个新系列是通过对内部HTS广告系列的热门歌曲进行线索优化而开发的。化合物3的效力比先前报道的吲哚羧酸1强得多，A549全细胞IC（50）为0.42 microM（50％FBS），人全血IC（50）为1.3 microM。口服剂量为30和100mg / kg时，它在豚鼠痛觉过敏模型中显示出明显的镇痛作用。
• Copper(0)/Selectfluor System-Promoted Oxidative Carbon–Carbon Bond Cleavage/Annulation of <i>o</i>-Aryl Chalcones: An Unexpected Synthesis of 9,10-Phenanthraquinone Derivatives
  作者：Hanyang Bao、Zheng Xu、Degui Wu、Haifeng Zhang、Hongwei Jin、Yunkui Liu

  DOI：10.1021/acs.joc.6b02212

  日期：2017.1.6

  A general and efficient protocol for the synthesis of 9,10-phenanthraquinone derivatives has been successfully developed involving a copper(0)/Selectfluor system-promoted oxidative carbon–carbon bond cleavage/annulation of o-aryl chalcones. A variety of substituted 9,10-phenanthraquinones were synthesized in moderate to good yields under mild reaction conditions.

  已经成功开发了一种合成9,10-菲蒽醌衍生物的通用有效方法，该方法涉及铜（0）/ Selectfluor系统促进的邻芳基查耳酮的氧化碳-碳键裂解/环化反应。在温和的反应条件下，以中等至良好的产率合成了多种取代的9,10-菲蒽醌。
• 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
  申请人：Chau Anh

  公开号：US20090075998A1

  公开（公告）日：2009-03-19

  The invention encompasses novel compounds of Formula I or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.

  该发明涵盖了式I的新化合物或其药学上可接受的盐。这些化合物是微粒体前列腺素E合酶-1（mPGES-1）酶的抑制剂，因此可用于治疗多种疾病或情况引起的疼痛和/或炎症，如骨关节炎，类风湿性关节炎和急性或慢性疼痛。还包括治疗由mPGES-1酶介导的疾病或情况的方法和制药组合物。
• 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
  申请人：Chau Anh

  公开号：US20070208017A1

  公开（公告）日：2007-09-06

  The invention encompasses novel compounds of Formula I or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.

  本发明涵盖了公式I的新化合物或其药学上可接受的盐。这些化合物是微粒体前列腺素E合成酶-1（mPGES-1）酶的抑制剂，因此可用于治疗各种疾病或病况引起的疼痛和/或炎症，如骨关节炎、类风湿性关节炎和急性或慢性疼痛。还包括治疗由mPGES-1酶介导的疾病或病况的方法和制药组合物。
• 2-(Phenyl or Heterocyclic)-1H-Phenanthro[9,10-D]Imidazoles
  申请人：Chau Anh

  公开号：US20090286772A1

  公开（公告）日：2009-11-19

  The invention encompasses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.

  该发明涵盖了公式（I）的新化合物或其药学上可接受的盐。这些化合物是微粒体前列腺素E合成酶-1（mPGES-1）酶的抑制剂，因此可用于治疗各种疾病或情况引起的疼痛和/或炎症，例如骨关节炎，类风湿性关节炎和急性或慢性疼痛。还包括治疗由mPGES-1酶介导的疾病或情况的方法和制药组合物。